Skip to main content

Table 1 Clinicopathological characteristics of 204 patients with diffuse large B-cell lymphoma (DLBCL) according to the expression of programmed cell death-ligand 1 (PD-L1) in tumor cells and tumor microenvironment

From: Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study

Characteristic

PD-L1 expression in tumor cells [cases (%)]

P value

PD-L1 expression in tumor microenvironment [cases (%)]

P value

Negative

Positive

Negative

Positive

Total

104

100

 

160

44

 

Gender

  

0.22

  

0.34

 Male

63 (60.6)

52 (52.0)

 

93 (58.1)

22 (50.0)

 

 Female

41 (39.4)

48 (48.0)

 

67 (41.9)

22 (50.0)

 

Age (years)

  

0.78

  

0.92

 ≤ 60

73 (70.2)

72 (72.0)

 

114 (71.2)

31 (70.5)

 

 > 60

31 (29.8)

28 (28.0)

 

46 (28.8)

13 (29.5)

 

Clinical stage

  

0.04

  

0.12

 I–II

58 (55.8)

42 (42.0)

 

83 (51.9)

17 (38.6)

 

 III–IV

46 (44.2)

58 (58.0)

 

77 (48.1)

27 (61.4)

 

B symptoms

  

0.74

  

0.22

 No

75 (72.1)

70 (70.0)

 

117 (73.1)

28 (63.6)

 

 Yes

29 (27.9)

30 (30.0)

 

43 (26.9)

16 (36.4)

 

Spleen involvement

  

0.19

  

0.22

 No

92 (88.5)

82 (82.0)

 

139 (86.9)

35 (79.5)

 

 Yes

12 (11.5)

18 (18.0)

 

21 (13.1)

9 (20.5)

 

IPI

  

0.09

  

0.18

 < 3

86 (82.7)

73 (73.0)

 

128 (80.0)

31 (70.5)

 

 ≥ 3

18 (17.3)

27 (27.0)

 

32 (20.0)

13 (29.5)

 

Extranodal involvement

  

0.67

  

0.88

 No

42 (40.4)

44 (44.0)

 

67 (41.9)

19 (43.2)

 

 Yes

62 (59.6)

56 (56.0)

 

93 (58.1)

25 (56.8)

 

Bulky diseasea

  

0.91

  

0.82

 No

56 (70.0)

63 (69.2)

 

92 (69.2)

27 (71.1)

 

 Yes

24 (30.0)

28 (30.8)

 

41 (30.8)

11 (28.9)

 

LDHb (U/L)

  

0.25

  

0.27

 ≤ 245

55 (55.6)

44 (47.3)

 

81 (53.6)

18 (43.9)

 

 > 245

44 (44.4)

49 (52.7)

 

70 (46.4)

23 (56.1)

 

ALPc (U/L)

  

0.17

  

0.42

 ≤ 110

93 (92.1)

86 (86.0)

 

138 (87.9)

41 (93.2)

 

 > 110

8 (7.9)

14 (14.0)

 

19 (12.1)

3 (6.8)

 

β2-MGd (mg/L)

  

0.06

  

0.01

 ≤ 2.52

25 (69.4)

21 (48.8)

 

41 (66.1)

5 (29.4)

 

 > 2.52

11 (30.6)

22 (51.2)

 

21 (33.9)

12 (70.6)

 

Ki-67e (%)

  

0.74

  

0.75

 < 90

45 (61.6)

45 (64.3)

 

70 (63.6)

20 (60.6)

 

 ≥ 90

28 (38.4)

25 (35.7)

 

40 (36.4)

13 (39.4)

 

GCB subtypef

  

0.02

  

0.04

 Non-GCB

61 (61.6)

77 (77.0)

 

102 (65.8)

36 (81.8)

 

 GCB

38 (38.4)

23 (23.0)

 

53 (34.2)

8 (18.2)

 

Rituximabg

  

0.62

  

0.10

 No

40 (43.0)

42 (46.7)

 

59 (41.5)

23 (56.1)

 

 Yes

53 (57.0)

48 (53.3)

 

83 (58.5)

18 (43.9)

 

First-line chemotherapy CRh

  

0.61

  

0.15

 No

31 (33.7)

31 (36.9)

 

46 (32.6)

16 (45.7)

 

 Yes

61 (66.3)

53 (63.1)

 

95 (67.4)

19 (54.3)

 

First-line chemotherapy resistancei

  

0.36

  

0.03

 No

83 (90.2)

72 (85.7)

 

128 (90.8)

27 (77.1)

 

 Yes

9 (9.8)

12 (14.3)

 

13 (9.2)

8 (22.9)

 

Relapse

  

0.12

  

0.93

 No

89 (85.6)

77 (77.0)

 

130 (81.2)

36 (81.8)

 

 Yes

15 (14.4)

23 (23.0)

 

30 (18.8)

8 (18.2)

 

Death

  

0.09

  

0.34

 No

69 (66.3)

55 (55.0)

 

100 (62.5)

24 (54.5)

 

 Yes

35 (33.7)

45 (45.0)

 

60 (37.5)

20 (45.5)

 
  1. IPI international prognostic index, LDH lactate dehydrogenase, ALP anaplastic lymphoma kinase, β2-MG β2-microglobulin, GCB germinal center B-cell-like, CR complete remission
  2. aThe data of 33 patients were missing
  3. bThe data of 12 patients were missing
  4. cThe data of 3 patients were missing
  5. dThe data of 125 patients were missing
  6. eThe data of 61 patients were missing
  7. fThe data of 5 patients were missing
  8. gThe data of 21 patients were missing
  9. hThe data of 28 patients were missing
  10. iThe data of 28 patients were missing
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us